News | July 22, 2014

SCAI Publishes Expert Consensus Recommendations for Treating Below-the-Knee Peripheral Artery Disease

July 22, 2014 -- The incidences of obesity and diabetes are increasing, and with them the number of patients with peripheral artery disease (PAD) in the arteries of the limbs. A new series of expert consensus recommendations developed by the Society for Cardiovascular Angiography and Interventions (SCAI) will help physicians determine the best course of action for patients whose blockages reduce blood flow to their limbs, putting them at risk for gangrene and amputation. The third paper in the series, e-published in Catheterization and Cardiovascular Interventions, outlines recommendations for treating infrapopliteal (IP), or “below-the-knee,” arterial disease.
 
Elderly patients and those with long-standing diabetes or chronic kidney disease are at greatest risk of developing such blockages, which can progress to critical limb ischemia (CLI), a painful and chronic condition that can lead to amputation. As the population ages and the number of patients with diabetes rises, the rate of CLI is expected to increase.
 
“Treating patients with IP arterial disease and CLI can relieve pain, heal ulcerations, preserve limbs and improve quality of life and function,” said Bruce H. Gray, D.O., FSCAI, professor of surgery/vascular medicine, University of South Carolina School of Medicine, and lead author of the consensus paper. “Depending on the patient’s condition, open surgery, an endovascular intervention or amputation are considered appropriate courses of action. These new recommendations aim to help guide physicians to make the best care decisions when an endovascular approach is appropriate.” 
 
The expert panel reviewed scientific data on each CLI treatment option, including balloon angioplasty, stents, atherectomy, as well as experimental therapies such as drug-coated balloons.Patients with severe disease, those with pain at rest and those with minor or major tissue loss should be considered for revascularization, with either surgery or endovascular treatment to prevent amputation or improve healing following amputation. Currently there is insufficient evidence to support treatment in those with asymptomatic disease.This document is the latest in SCAI’s series of recommendations for treating PAD. Previous documents included “SCAI Expert Consensus Document for Aorto-Iliac Arterial Intervention Appropriate Use” and “SCAI Expert Consensus Document for Femoral-Popliteal Arterial Intervention Appropriate Use.” The final document in the series will focus on renal artery stenosis and will be published in Catheterization and Cardiovascular Interventions later this summer.
 
“SCAI is committed to providing physicians with the necessary tools to appropriately diagnose and treat patients,” said SCAI 2014-15 President Charles Chambers, M.D., FSCAI. “These recommendations were developed based on our belief that patient safety and quality should always be physicians’ top priority.” The paper, titled “SCAI Expert Consensus Statement for Infrapopliteal Arterial Intervention Appropriate Use,” is e-published in Catheterization and Cardiovascular Interventions.
 
For more information: www.SCAI.org

Related Content

Intact Vascular Inc. received U.S. Food and Drug Administration (FDA) market clearance for the Tack Endovascular System. This is a purpose-built dissection repair device implanted post-angioplasty in patients with peripheral arterial disease (PAD).
Technology | Peripheral Artery Disease (PAD) | April 15, 2019
April 15, 2019 – Intact Vascular Inc. received U.S.
The Boston Scientific Eluvia self-expanding, drug-eluting peripheral stent. It outperformed the Cook Zilver stent in the IMPERIAL Trial presented at TCT 2018.

The Boston Scientific Eluvia self-expanding, drug-eluting peripheral stent. It outperformed the Cook Zilver stent in the IMPERIAL Trial presented at TCT 2018.

Feature | Peripheral Artery Disease (PAD) | January 30, 2019 | Dave Fornell, Editor
In recent years, there has been a lot of focus by vendors on developing better stenting technologies to treat...
The safety of paclitaxel-eluting stents and drug-coated balloons was called into question in a recent study that showed higher mortality rates after two years. The Cook Zilver PTX paclitaxel-eluting peripheral stent is among the devices included in that study.

The safety of paclitaxel-eluting stents and drug-coated balloons was called into question in a recent study that showed higher mortality rates after two years. The Cook Zilver PTX paclitaxel-eluting peripheral stent is among the devices included in that study.

Feature | Peripheral Artery Disease (PAD) | January 25, 2019 | Dave Fornell, Editor
The anti-proliferative drug paclitaxel has been used as a coating on coronary stents to prevent restenosis since 2003
Lumee Oxygen Platform Measures Treatment Response in Critical Limb Ischemia
News | Peripheral Artery Disease (PAD) | January 25, 2019
January 25, 2019 — Profusa announced promising...
BEST-CLI Trial Examining Critical Limb Ischemia Treatment Options Nears Enrollment Goal
News | Peripheral Artery Disease (PAD) | January 23, 2019
A new report in the Journal of Vascular Surgery chronicles a multi-site randomized controlled trial comparing treatment...
FDA Issues Letter About Paclitaxel Coated Balloons and Eluting Stents
News | Peripheral Artery Disease (PAD) | January 17, 2019
The U.S. Food and Drug Administration (FDA) issued a letter Jan. 17, 2019, to healthcare providers regarding a recent...
New Appropriate Use Criteria Released for Peripheral Artery Interventions
News | Peripheral Artery Disease (PAD) | December 19, 2018
A new set of appropriate use criteria (AUC) released Dec. 17 by a group of cardiovascular professional societies...
Lithotripsy Safe and Effective in Calcified Stenotic Peripheral Arteries
News | Peripheral Artery Disease (PAD) | December 04, 2018
New results from the DISRUPT PAD II study showed no perforations, embolization, reflow or abrupt closures with the...
Lutonix 014 Drug-Coated Balloon Safe and Effective Below the Knee
News | Peripheral Artery Disease (PAD) | November 07, 2018
The Lutonix Drug-Coated Balloon (DCB) showed statistically significant safety equivalence with a standard percutaneous...
Overlay Init